CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: carbamate fungicide
Accession: CHEBI:87061
browse the term
Definition: Compounds that contain a carbamate ester moiety as a key feature of their structure and which have been used as fungicides.
Synonyms: related_synonym: carbamate fungicides
G
Ar
androgen receptor
multiple interactions
ISO
3-iodo-2-propynylbutylcarbamate inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]
CTD
PMID:33049310
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Esr1
estrogen receptor 1
multiple interactions
ISO
3-iodo-2-propynylbutylcarbamate binds to and results in decreased activity of ESR1 protein
CTD
PMID:33049310
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Nr1i2
nuclear receptor subfamily 1, group I, member 2
multiple interactions
ISO
3-iodo-2-propynylbutylcarbamate binds to and results in increased activity of NR1I2 protein
CTD
PMID:33049310
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
G
Pparg
peroxisome proliferator-activated receptor gamma
multiple interactions
ISO
3-iodo-2-propynylbutylcarbamate binds to and results in increased activity of PPARG protein
CTD
PMID:33049310
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
G
Thra
thyroid hormone receptor alpha
multiple interactions
ISO
3-iodo-2-propynylbutylcarbamate binds to and results in increased activity of THRA protein
CTD
PMID:33049310
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
G
Tp53
tumor protein p53
affects activity
ISO
3-iodo-2-propynylbutylcarbamate affects the activity of TP53 protein
CTD
PMID:35435491
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Adcy7
adenylate cyclase 7
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of ADCY7 mRNA
CTD
PMID:16861626
NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311
G
Arl4c
ADP ribosylation factor like GTPase 4C
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of ARL4C mRNA
CTD
PMID:16861626
NCBI chr 9:89,300,335...89,303,770
Ensembl chr 9:89,298,005...89,304,513
G
Bag3
BAG cochaperone 3
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of BAG3 mRNA
CTD
PMID:16861626
NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
G
Ccl2
C-C motif chemokine ligand 2
increases expression
ISO
Albendazole results in increased expression of CCL2 protein
CTD
PMID:20116850
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
G
Ccl3
C-C motif chemokine ligand 3
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of CCL3 protein
CTD
PMID:16861626
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
G
Ccr7
C-C motif chemokine receptor 7
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of CCR7 mRNA
CTD
PMID:16861626
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
G
Cct3
chaperonin containing TCP1 subunit 3
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of CCT3 mRNA
CTD
PMID:16861626
NCBI chr 2:173,765,701...173,790,353
Ensembl chr 2:173,765,698...173,790,757
G
Cd86
CD86 molecule
multiple interactions
ISO
[Albendazole co-treated with CYP3A4 protein] results in increased expression of CD86 protein
CTD
PMID:22785256
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
G
Ctsl
cathepsin L
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of CTSL mRNA
CTD
PMID:16861626
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
G
Cyp1a1
cytochrome P450, family 1, subfamily a, polypeptide 1
increases activity decreases activity increases expression
ISO
Albendazole results in increased activity of CYP1A1 promoter; Albendazole results in increased activity of CYP1A1 protein Albendazole results in decreased activity of CYP1A1 protein Albendazole results in increased expression of CYP1A1 mRNA
CTD
PMID:12451431 PMID:16714371 PMID:18502397 PMID:33814510
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
G
Cyp1a2
cytochrome P450, family 1, subfamily a, polypeptide 2
increases expression affects metabolic processing
ISO
Albendazole results in increased expression of CYP1A2 mRNA CYP1A2 protein affects the metabolism of Albendazole
CTD
PMID:12451431 PMID:12920490
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
G
Cyp1b1
cytochrome P450, family 1, subfamily b, polypeptide 1
decreases activity
ISO
Albendazole results in decreased activity of CYP1B1 protein
CTD
PMID:33814510
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
G
Cyp3a2
cytochrome P450, family 3, subfamily a, polypeptide 2
multiple interactions
EXP ISO
[SOD2 co-treated with CYP3A4] affects the susceptibility to Albendazole [Albendazole co-treated with CYP3A4 protein] results in increased expression of CD86 protein; [Albendazole co-treated with CYP3A4 protein] results in increased expression of ICAM1 protein
CTD
PMID:19501153 PMID:22785256
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
G
Dnajb1
DnaJ heat shock protein family (Hsp40) member B1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of DNAJB1 mRNA
CTD
PMID:16861626
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
G
Dpysl2
dihydropyrimidinase-like 2
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of DPYSL2 mRNA
CTD
PMID:16861626
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
G
Gem
GTP binding protein overexpressed in skeletal muscle
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of GEM mRNA
CTD
PMID:16861626
NCBI chr 5:25,214,309...25,225,222
Ensembl chr 5:25,214,309...25,225,222
G
Gpr183
G protein-coupled receptor 183
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of GPR183 mRNA
CTD
PMID:16861626
NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559
G
Hsf1
heat shock transcription factor 1
increases activity
ISO
Albendazole results in increased activity of HSF1 protein
CTD
PMID:34170685
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
G
Hsp90aa1
heat shock protein 90 alpha family class A member 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSP90AA1 mRNA
CTD
PMID:16861626
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
G
Hsp90ab1
heat shock protein 90 alpha family class B member 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSP90AB1 mRNA
CTD
PMID:16861626
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
G
Hspa4
heat shock protein family A (Hsp70) member 4
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSPA4 mRNA
CTD
PMID:16861626
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
G
Hspa8
heat shock protein family A (Hsp70) member 8
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSPA8 mRNA
CTD
PMID:16861626
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
G
Hspd1
heat shock protein family D (Hsp60) member 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSPD1 mRNA
CTD
PMID:16861626
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
G
Hspe1
heat shock protein family E (Hsp10) member 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSPE1 mRNA
CTD
PMID:16861626
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
G
Hsph1
heat shock protein family H (Hsp110) member 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSPH1 mRNA
CTD
PMID:16861626
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
G
Icam1
intercellular adhesion molecule 1
multiple interactions
ISO
[Albendazole co-treated with CYP3A4 protein] results in increased expression of ICAM1 protein
CTD
PMID:22785256
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
G
Il10
interleukin 10
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of IL10 protein
CTD
PMID:16861626
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
G
Il1a
interleukin 1 alpha
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of IL1A protein
CTD
PMID:16861626
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
G
Il1r1
interleukin 1 receptor type 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of IL1R1 mRNA
CTD
PMID:16861626
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
G
Il6r
interleukin 6 receptor
increases expression
ISO
Albendazole results in increased expression of IL6R protein modified form
CTD
PMID:20116850
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
G
Map3k8
mitogen-activated protein kinase kinase kinase 8
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of MAP3K8 mRNA
CTD
PMID:16861626
NCBI chr17:53,382,908...53,403,216
Ensembl chr17:53,383,131...53,403,216
G
Mapt
microtubule-associated protein tau
decreases expression
ISO
Albendazole results in decreased expression of MAPT mRNA; Albendazole results in decreased expression of MAPT protein
CTD
PMID:16930453
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
G
Nr1h4
nuclear receptor subfamily 1, group H, member 4
multiple interactions
ISO
Albendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
CTD
PMID:25257666
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
G
Ppid
peptidylprolyl isomerase D
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of PPID mRNA
CTD
PMID:16861626
NCBI chr 2:164,727,803...164,740,168
Ensembl chr 2:164,727,779...164,740,221
G
Ppif
peptidylprolyl isomerase F
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of PPIF mRNA
CTD
PMID:16861626
NCBI chr16:1,257,197...1,263,919
Ensembl chr16:1,257,106...1,263,913
G
Ptges3
prostaglandin E synthase 3
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of PTGES3 mRNA
CTD
PMID:16861626
NCBI chr 7:490,698...507,759
Ensembl chr 7:490,656...508,084
G
RT1-DMb
RT1 class II, locus DMb
affects expression
ISO
Albendazole affects the expression of HLA-DMB mRNA
CTD
PMID:25811541
NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340
G
Skap2
src kinase associated phosphoprotein 2
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of SKAP2 mRNA
CTD
PMID:16861626
NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:80,950,580...81,100,891
G
Sod2
superoxide dismutase 2
multiple interactions
EXP
[SOD2 co-treated with CYP3A4] affects the susceptibility to Albendazole
CTD
PMID:19501153
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
G
Sphk1
sphingosine kinase 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of SPHK1 mRNA
CTD
PMID:16861626
NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240
G
St13
ST13, Hsp70 interacting protein
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of ST13 mRNA
CTD
PMID:16861626
NCBI chr 7:112,891,007...112,925,727
Ensembl chr 7:112,844,375...112,925,945
G
Tcp1
t-complex 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of TCP1 mRNA
CTD
PMID:16861626
NCBI chr 1:47,829,061...47,836,809
Ensembl chr 1:47,828,652...47,836,839
G
Tgif1
TGFB-induced factor homeobox 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of TGIF1 mRNA
CTD
PMID:16861626
NCBI chr 9:110,748,094...110,757,714
Ensembl chr 9:110,720,921...110,757,802
G
Tnf
tumor necrosis factor
multiple interactions increases secretion
ISO
U 0126 inhibits the reaction [Albendazole results in increased secretion of TNF protein]
CTD
PMID:20848085
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Tp53
tumor protein p53
affects activity
ISO
Albendazole affects the activity of TP53 protein
CTD
PMID:35435491
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Tsc22d1
TSC22 domain family, member 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of TSC22D1 mRNA
CTD
PMID:16861626
NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958
G
Vegfa
vascular endothelial growth factor A
increases expression
ISO
Albendazole results in increased expression of VEGFA protein
CTD
PMID:20116850
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
G
Abcg2
ATP binding cassette subfamily G member 2
affects transport
ISO
ABCG2 protein affects the transport of albendazole sulfoxide
CTD
PMID:15703302
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
G
Nr1h4
nuclear receptor subfamily 1, group H, member 4
multiple interactions
ISO
albendazole sulfoxide inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
CTD
PMID:25257666
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
G
Tp53
tumor protein p53
affects activity
ISO
albendazole sulfoxide affects the activity of TP53 protein
CTD
PMID:35435491
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Adam33
ADAM metallopeptidase domain 33
multiple interactions increases expression
ISO
ORMDL3 protein affects the reaction [Benomyl results in increased expression of ADAM33 protein]
CTD
PMID:27784618
NCBI chr 3:118,262,395...118,283,456
Ensembl chr 3:118,271,029...118,283,461
G
Akt1
AKT serine/threonine kinase 1
decreases expression
EXP
Benomyl results in decreased expression of AKT1 mRNA
CTD
PMID:33930522
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
G
Aldh2
aldehyde dehydrogenase 2 family member
decreases activity
ISO EXP
Benomyl metabolite results in decreased activity of ALDH2 protein; Benomyl results in decreased activity of ALDH2 protein
CTD
PMID:9585485 PMID:10513990 PMID:11142365 PMID:15331769 PMID:17010440
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
G
Aldh5a1
aldehyde dehydrogenase 5 family, member A1
decreases activity
EXP
Benomyl results in decreased activity of ALDH5A1 protein
CTD
PMID:17010440
NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
G
Ampd3
adenosine monophosphate deaminase 3
decreases expression
EXP
Benomyl results in decreased expression of AMPD3 mRNA
CTD
PMID:15885261
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
G
Ar
androgen receptor
multiple interactions
ISO
Benomyl inhibits the reaction [Dihydrotestosterone affects the localization of and results in increased phosphorylation of AR protein]
CTD
PMID:25324206
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Bax
BCL2 associated X, apoptosis regulator
multiple interactions
ISO
Benomyl inhibits the reaction [BCL2 protein binds to BAX protein]
CTD
PMID:16903866
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
G
Bcl2
BCL2, apoptosis regulator
multiple interactions increases phosphorylation
ISO
Benomyl inhibits the reaction [BCL2 protein binds to BAX protein] Benomyl results in increased phosphorylation of BCL2 protein
CTD
PMID:16903866
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
G
Bub1b
BUB1 mitotic checkpoint serine/threonine kinase B
increases expression
ISO
Benomyl results in increased expression of BUB1B protein
CTD
PMID:16903866
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
G
Car2
carbonic anhydrase 2
increases expression
EXP
Benomyl results in increased expression of CA2 mRNA
CTD
PMID:15885261
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
G
Ccl17
C-C motif chemokine ligand 17
increases expression multiple interactions
ISO
Benomyl results in increased expression of CCL17 mRNA ORMDL3 protein affects the reaction [Benomyl results in increased expression of CCL17 mRNA]
CTD
PMID:27784618
NCBI chr19:10,202,128...10,203,903
Ensembl chr19:10,202,128...10,203,819
G
Ccnb1
cyclin B1
increases response to substance
ISO
CCNB1 protein results in increased susceptibility to Benomyl
CTD
PMID:11960377
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
G
Ccnb2
cyclin B2
increases response to substance
ISO
CCNB2 protein results in increased susceptibility to Benomyl
CTD
PMID:11960377
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
G
Cd38
CD38 molecule
decreases expression
EXP
Benomyl results in decreased expression of CD38 mRNA
CTD
PMID:15885261
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
G
Cyp17a1
cytochrome P450, family 17, subfamily a, polypeptide 1
decreases expression multiple interactions
ISO
Benomyl results in decreased expression of CYP17A1 mRNA Benomyl results in decreased expression of and results in decreased activity of CYP17A1 protein
CTD
PMID:25324206
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
G
Cyp19a1
cytochrome P450, family 19, subfamily a, polypeptide 1
increases activity increases expression
ISO
Benomyl results in increased activity of CYP19A1 protein Benomyl results in increased expression of CYP19A1 mRNA
CTD
PMID:14691014 PMID:25543211
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
G
Ddit3
DNA-damage inducible transcript 3
multiple interactions increases expression
ISO
Acetylcysteine inhibits the reaction [Benomyl results in increased expression of DDIT3 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of DDIT3 protein]
CTD
PMID:27784618
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
G
Eif2ak3
eukaryotic translation initiation factor 2 alpha kinase 3
increases expression multiple interactions
ISO
Benomyl results in increased expression of EIF2AK3 protein Acetylcysteine inhibits the reaction [Benomyl results in increased expression of EIF2AK3 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of EIF2AK3 protein]
CTD
PMID:27784618
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
G
Ern1
endoplasmic reticulum to nucleus signaling 1
multiple interactions increases expression
ISO
Acetylcysteine inhibits the reaction [Benomyl results in increased expression of ERN1 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of ERN1 protein]
CTD
PMID:27784618
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
G
Esr1
estrogen receptor 1
multiple interactions affects binding
ISO
Benomyl binds to and results in increased activity of ESR1 protein; Benomyl inhibits the reaction [Estradiol binds to ESR1 protein] Benomyl binds to ESR1 protein
CTD
PMID:14579009 PMID:16626760
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Fgfr4
fibroblast growth factor receptor 4
increases expression
EXP
Benomyl results in increased expression of FGFR4 mRNA
CTD
PMID:15885261
NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
G
Gipc1
GIPC PDZ domain containing family, member 1
increases expression
EXP
Benomyl results in increased expression of GIPC1 mRNA
CTD
PMID:15885261
NCBI chr19:24,474,291...24,487,083
Ensembl chr19:24,453,123...24,486,997
G
Glyat
glycine-N-acyltransferase
increases expression
EXP
Benomyl results in increased expression of GLYAT mRNA
CTD
PMID:15885261
NCBI chr 1:209,704,213...209,724,949
Ensembl chr 1:209,704,268...209,724,942
G
Hdac1
histone deacetylase 1
decreases activity
ISO
Benomyl results in decreased activity of HDAC1 protein
CTD
PMID:25543211
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
G
Hspa5
heat shock protein family A (Hsp70) member 5
increases expression multiple interactions
ISO
Benomyl results in increased expression of HSPA5 protein Acetylcysteine inhibits the reaction [Benomyl results in increased expression of HSPA5 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of HSPA5 protein]
CTD
PMID:27784618
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
G
Hspb1
heat shock protein family B (small) member 1
increases expression
EXP
Benomyl results in increased expression of HSPB1 mRNA
CTD
PMID:15885261
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
G
Ifnb1
interferon beta 1
multiple interactions
ISO
Benomyl inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]
CTD
PMID:18177342
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
G
Itga5
integrin subunit alpha 5
decreases expression
ISO
Benomyl results in decreased expression of ITGA5 mRNA
CTD
PMID:25530041
NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837
G
Itgb1
integrin subunit beta 1
decreases expression
ISO
Benomyl results in decreased expression of ITGB1 mRNA
CTD
PMID:25530041
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
G
Klk1c10
kallikrein 1-related peptidase C10
multiple interactions
ISO
Benomyl inhibits the reaction [Dihydrotestosterone results in increased secretion of KLK3 protein]
CTD
PMID:25324206
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
G
Mapk8
mitogen-activated protein kinase 8
increases expression
EXP
Benomyl results in increased expression of MAPK8 mRNA
CTD
PMID:33930522
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
G
Mir21
microRNA 21
decreases expression
EXP
Benomyl results in decreased expression of MIR21 mRNA
CTD
PMID:33930522
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
G
Mmp2
matrix metallopeptidase 2
decreases expression multiple interactions increases expression
ISO
Benomyl results in decreased expression of MMP2 mRNA ORMDL3 protein affects the reaction [Benomyl results in increased expression of MMP2 protein]
CTD
PMID:25530041 PMID:27784618
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
G
Mmp9
matrix metallopeptidase 9
decreases expression
EXP ISO
Benomyl results in decreased expression of MMP9 protein Benomyl results in decreased expression of MMP9 mRNA
CTD
PMID:10026946 PMID:25530041
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
G
Mmrn1
multimerin 1
increases expression
EXP
Benomyl results in increased expression of MMRN1 mRNA
CTD
PMID:15885261
NCBI chr 4:89,875,408...89,950,814
Ensembl chr 4:89,903,174...89,950,474
G
Msmb
microseminoprotein, beta
increases expression
EXP
Benomyl results in increased expression of MSMB mRNA
CTD
PMID:15885261
NCBI chr16:7,366,536...7,387,124
Ensembl chr16:7,366,536...7,387,123
G
Mt2A
metallothionein 2A
increases expression
EXP
Benomyl results in increased expression of MT2A mRNA
CTD
PMID:15885261
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
G
Nfkb1
nuclear factor kappa B subunit 1
multiple interactions
ISO
Benomyl inhibits the reaction [Lipopolysaccharides results in increased activity of NFKB1 protein]
CTD
PMID:17015962
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
G
Nr1h4
nuclear receptor subfamily 1, group H, member 4
multiple interactions
ISO
Benomyl inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
CTD
PMID:25257666
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
G
Or10al27
olfactory receptor family 10 subfamily AL member 27
increases expression
EXP
Benomyl results in increased expression of OR10AL27 mRNA
CTD
PMID:15885261
NCBI chr20:789,272...790,237
Ensembl chr20:761,025...765,744 Ensembl chr20:761,025...765,744
G
Or13p4
olfactory receptor family 13 subfamily P member 4
increases expression
EXP
Benomyl results in increased expression of OR13P4 mRNA
CTD
PMID:15885261
NCBI chr 5:132,216,822...132,217,769
Ensembl chr 5:132,215,327...132,221,481
G
Or9s23b
olfactory receptor family 9 subfamily S member 23B
increases expression
EXP
Benomyl results in increased expression of OR9S23B mRNA
CTD
PMID:15885261
NCBI chr 9:93,117,328...93,118,299
Ensembl chr 9:93,115,232...93,123,441
G
Ormdl3
ORMDL sphingolipid biosynthesis regulator 3
multiple interactions increases expression
ISO
Acetylcysteine inhibits the reaction [Benomyl results in increased expression of ORMDL3 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of ORMDL3 protein]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of ADAM33 protein]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of CCL17 mRNA]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of CXCL8 mRNA]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of MMP2 protein]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of TSLP mRNA]
CTD
PMID:27784618
NCBI chr10:83,590,052...83,596,035
Ensembl chr10:83,590,071...83,598,620
G
Park7
Parkinsonism associated deglycase
decreases activity
ISO
Benomyl results in decreased activity of PARK7 protein
CTD
PMID:36842454
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
G
Parp1
poly (ADP-ribose) polymerase 1
increases cleavage
ISO
Benomyl results in increased cleavage of PARP1 protein
CTD
PMID:16903866
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
G
Plau
plasminogen activator, urokinase
decreases expression
ISO
Benomyl results in decreased expression of PLAU mRNA
CTD
PMID:25530041
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
G
Pten
phosphatase and tensin homolog
increases expression
EXP
Benomyl results in increased expression of PTEN mRNA
CTD
PMID:33930522
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
G
Rela
RELA proto-oncogene, NF-kB subunit
increases expression
EXP
Benomyl results in increased expression of RELA mRNA
CTD
PMID:33930522
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
G
Scd
stearoyl-CoA desaturase
decreases expression
EXP
Benomyl results in decreased expression of SCD1 mRNA
CTD
PMID:15885261
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
G
Serpine2
serpin family E member 2
increases expression
ISO
Benomyl results in increased expression of SERPINE2 mRNA
CTD
PMID:25530041
NCBI chr 9:81,124,746...81,188,866
Ensembl chr 9:81,124,804...81,188,826
G
Sh2d4a
SH2 domain containing 4A
increases expression
EXP
Benomyl results in increased expression of SH2D4A mRNA
CTD
PMID:15885261
NCBI chr16:21,339,010...21,409,360
Ensembl chr16:21,340,015...21,409,260
G
Timp1
TIMP metallopeptidase inhibitor 1
increases expression
ISO
Benomyl results in increased expression of TIMP1 mRNA
CTD
PMID:25530041
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
G
Timp2
TIMP metallopeptidase inhibitor 2
increases expression
ISO
Benomyl results in increased expression of TIMP2 mRNA
CTD
PMID:25530041
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
G
Tnf
tumor necrosis factor
decreases expression
EXP
Benomyl results in decreased expression of TNF mRNA
CTD
PMID:33930522
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Tp53
tumor protein p53
affects activity
ISO
Benomyl affects the activity of TP53 protein
CTD
PMID:35435491
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Tslp
thymic stromal lymphopoietin
increases expression multiple interactions
ISO
Benomyl results in increased expression of TSLP mRNA ORMDL3 protein affects the reaction [Benomyl results in increased expression of TSLP mRNA]
CTD
PMID:27784618
NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548
G
Uba1
ubiquitin-like modifier activating enzyme 1
multiple interactions
ISO
Benomyl results in increased activity of and results in increased ubiquitination of UBA1 protein
CTD
PMID:25714994
NCBI chr X:1,508,700...1,530,677
Ensembl chr X:1,508,666...1,530,636
G
Vasp
vasodilator-stimulated phosphoprotein
multiple interactions
EXP
Benomyl inhibits the reaction [Nitroglycerin results in increased phosphorylation of VASP protein]; Benomyl inhibits the reaction [Pentaerythritol Tetranitrate results in increased phosphorylation of VASP protein]
CTD
PMID:15331769
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
G
Abi2
abl-interactor 2
increases expression
EXP
carbendazim results in increased expression of ABI2 mRNA
CTD
PMID:22952946
NCBI chr 9:61,827,186...61,905,703
Ensembl chr 9:61,827,139...61,905,699
G
Acaca
acetyl-CoA carboxylase alpha
increases expression
ISO
carbendazim results in increased expression of ACACA mRNA
CTD
PMID:26071454
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
G
Ache
acetylcholinesterase
multiple interactions
EXP
[carbendazim co-treated with mancozeb] results in increased activity of ACHE protein
CTD
PMID:33217513
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
G
Agpat2
1-acylglycerol-3-phosphate O-acyltransferase 2
increases expression
ISO
carbendazim results in increased expression of AGPAT2 mRNA
CTD
PMID:26071454
NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371
G
Ahr
aryl hydrocarbon receptor
multiple interactions affects localization
ISO
AHR protein affects the reaction [carbendazim results in increased expression of CYP1A1 protein] carbendazim affects the localization of AHR protein
CTD
PMID:27286660
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
G
Alb
albumin
decreases expression
EXP
carbendazim results in decreased expression of ALB protein
CTD
PMID:35437878
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
G
Anxa10
annexin A10
increases expression
ISO
carbendazim results in increased expression of ANXA10 mRNA
CTD
PMID:32194361
NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648
G
Arg1
arginase 1
decreases expression
ISO
carbendazim results in decreased expression of ARG1 mRNA
CTD
PMID:32194361
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
G
Bag1
BAG cochaperone 1
increases expression
EXP
carbendazim results in increased expression of BAG1 mRNA
CTD
PMID:22952946
NCBI chr 5:56,068,494...56,081,075
Ensembl chr 5:56,068,494...56,081,075
G
Bax
BCL2 associated X, apoptosis regulator
increases expression
EXP
carbendazim results in increased expression of BAX mRNA; carbendazim results in increased expression of BAX protein
CTD
PMID:35437878 PMID:35513110
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
G
Bcl2
BCL2, apoptosis regulator
decreases expression
EXP
carbendazim results in decreased expression of BCL2 mRNA
CTD
PMID:35437878 PMID:35513110
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
G
Bcl2l14
Bcl2-like 14
increases expression
EXP
carbendazim results in increased expression of BCL2L14 mRNA
CTD
PMID:22952946
NCBI chr 4:167,217,561...167,258,723
Ensembl chr 4:167,219,871...167,258,086
G
Bub1b
BUB1 mitotic checkpoint serine/threonine kinase B
increases activity
ISO
carbendazim results in increased activity of BUB1B protein
CTD
PMID:37506866
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
G
Casp3
caspase 3
increases activity multiple interactions increases expression
ISO EXP
carbendazim results in increased activity of CASP3 protein Chitosan inhibits the reaction [carbendazim results in increased expression of CASP3 protein]
CTD
PMID:30851412 PMID:35705592
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
G
Cat
catalase
decreases activity decreases expression multiple interactions
EXP
carbendazim results in decreased activity of CAT protein carbendazim results in decreased expression of CAT protein [Chlorpyrifos co-treated with carbendazim] results in decreased activity of CAT protein; Chitosan inhibits the reaction [carbendazim results in decreased expression of CAT protein]
CTD
PMID:27268782 PMID:35513110 PMID:35705592
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
G
Ccnb1
cyclin B1
increases expression
ISO
carbendazim results in increased expression of CCNB1 protein
CTD
PMID:37506866
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
G
Clca2
chloride channel accessory 2
multiple interactions
EXP
[carbendazim co-treated with 2,5-hexanedione] results in decreased expression of CLCA2 mRNA
CTD
PMID:22382377
NCBI chr 2:233,993,619...234,022,691
Ensembl chr 2:233,995,078...234,022,199
G
Cldn11
claudin 11
multiple interactions
EXP
[carbendazim co-treated with iprodione] results in decreased expression of CLDN11 protein
CTD
PMID:28576679
NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050
G
Clu
clusterin
decreases expression increases expression
EXP
carbendazim results in decreased expression of CLU mRNA carbendazim results in increased expression of CLU mRNA
CTD
PMID:22952946 PMID:27466211
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
G
Cyp19a1
cytochrome P450, family 19, subfamily a, polypeptide 1
increases activity increases expression
ISO
carbendazim results in increased activity of CYP19A1 protein carbendazim results in increased expression of CYP19A1 mRNA
CTD
PMID:14691014
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
G
Cyp1a1
cytochrome P450, family 1, subfamily a, polypeptide 1
increases expression multiple interactions
ISO EXP
carbendazim results in increased expression of CYP1A1 mRNA; carbendazim results in increased expression of CYP1A1 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [carbendazim results in increased expression of CYP1A1 protein]; AHR protein affects the reaction [carbendazim results in increased expression of CYP1A1 protein]; salicylamide inhibits the reaction [carbendazim results in increased expression of CYP1A1 protein]
CTD
PMID:10103034 PMID:21784029 PMID:27286660 PMID:32194361
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
G
Cyp1a2
cytochrome P450, family 1, subfamily a, polypeptide 2
increases expression
ISO
carbendazim results in increased expression of CYP1A2 mRNA; carbendazim results in increased expression of CYP1A2 protein
CTD
PMID:21784029
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
G
Cyp2b3
cytochrome P450, family 2, subfamily b, polypeptide 3
increases expression
ISO
carbendazim results in increased expression of CYP2B6 mRNA
CTD
PMID:22310298
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
G
Cyp2c6
cytochrome P450, family 2, subfamily C, polypeptide 6
decreases expression
ISO
carbendazim results in decreased expression of CYP2C19 protein
CTD
PMID:32194361
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
G
Cyp2d4
cytochrome P450, family 2, subfamily d, polypeptide 4
decreases activity
ISO
carbendazim results in decreased activity of CYP2D6 protein
CTD
PMID:20183062
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
G
Cyp3a2
cytochrome P450, family 3, subfamily a, polypeptide 2
increases expression
ISO
carbendazim results in increased expression of CYP3A4 mRNA
CTD
PMID:22310298
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
G
Cyp7a1
cytochrome P450 family 7 subfamily A member 1
decreases expression
ISO
carbendazim results in decreased expression of CYP7A1 mRNA; carbendazim results in decreased expression of CYP7A1 protein
CTD
PMID:32194361
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
G
Dgat1
diacylglycerol O-acyltransferase 1
increases expression
ISO
carbendazim results in increased expression of DGAT1 mRNA
CTD
PMID:26071454
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
G
Dgat2
diacylglycerol O-acyltransferase 2
increases expression
ISO
carbendazim results in increased expression of DGAT2 mRNA
CTD
PMID:26071454
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
G
Dnaaf11
dynein axonemal assembly factor 11
decreases expression
EXP
carbendazim results in decreased expression of DNAAF11 mRNA
CTD
PMID:27466211
NCBI chr 7:98,141,525...98,245,906
Ensembl chr 7:98,144,763...98,245,837
G
Dpp7
dipeptidylpeptidase 7
multiple interactions
EXP
[carbendazim co-treated with 2,5-hexanedione] results in decreased expression of DPP7 mRNA
CTD
PMID:22382377
NCBI chr 3:8,165,091...8,169,343
Ensembl chr 3:8,165,091...8,169,355
G
Esr1
estrogen receptor 1
decreases expression affects localization
EXP ISO
carbendazim results in decreased expression of ESR1 mRNA carbendazim affects the localization of ESR1 protein
CTD
PMID:28576679 PMID:37506866
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Esr2
estrogen receptor 2
decreases expression
EXP
carbendazim results in decreased expression of ESR2 mRNA
CTD
PMID:28576679
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
G
Fabp9
fatty acid binding protein 9
multiple interactions decreases expression
EXP
Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein] carbendazim results in decreased expression of FABP9 mRNA; carbendazim results in decreased expression of FABP9 protein
CTD
PMID:33965443
NCBI chr 2:91,591,842...91,595,873
Ensembl chr 2:91,592,298...91,595,873
G
Fank1
fibronectin type III and ankyrin repeat domains 1
increases expression
EXP
carbendazim results in increased expression of FANK1 mRNA
CTD
PMID:22952946
NCBI chr 1:188,577,512...188,685,501
Ensembl chr 1:188,577,575...188,685,504
G
Foxa2
forkhead box A2
increases expression
ISO
carbendazim results in increased expression of FOXA2 mRNA
CTD
PMID:26071454
NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
G
Fshb
follicle stimulating hormone subunit beta
decreases expression multiple interactions
EXP
carbendazim results in decreased expression of FSHB protein Carnitine inhibits the reaction [carbendazim results in decreased expression of FSHB protein]
CTD
PMID:33965443
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
G
G6pc1
glucose-6-phosphatase catalytic subunit 1
decreases expression
ISO
carbendazim results in decreased expression of G6PC1 mRNA
CTD
PMID:32194361
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
G
Gfap
glial fibrillary acidic protein
increases expression
EXP
carbendazim results in increased expression of GFAP protein
CTD
PMID:35513110
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
G
Gja1
gap junction protein, alpha 1
multiple interactions
EXP
[carbendazim co-treated with iprodione] results in decreased expression of GJA1 protein
CTD
PMID:28576679
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
G
Got1
glutamic-oxaloacetic transaminase 1
increases secretion multiple interactions
EXP
carbendazim results in increased secretion of GOT1 protein Chitosan inhibits the reaction [carbendazim results in increased secretion of GOT1 protein]
CTD
PMID:35705592
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
G
Gpt
glutamic--pyruvic transaminase
increases expression increases secretion multiple interactions
EXP
carbendazim results in increased expression of GPT protein carbendazim results in increased secretion of GPT protein Chitosan inhibits the reaction [carbendazim results in increased secretion of GPT protein]
CTD
PMID:35437878 PMID:35705592
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
G
Hmox1
heme oxygenase 1
multiple interactions decreases expression
EXP
Chitosan inhibits the reaction [carbendazim results in decreased expression of HMOX1 mRNA]
CTD
PMID:35705592
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
G
Ift81
intraflagellar transport 81
decreases expression
EXP
carbendazim results in decreased expression of IFT81 mRNA
CTD
PMID:22952946 PMID:27466211
NCBI chr12:33,957,744...34,037,164
Ensembl chr12:33,957,806...34,037,057
G
Il10
interleukin 10
multiple interactions decreases expression
EXP
Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]
CTD
PMID:33965443
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
G
Il1b
interleukin 1 beta
increases expression
ISO EXP
carbendazim results in increased expression of IL1B mRNA; carbendazim results in increased expression of IL1B protein
CTD
PMID:26071454 PMID:35513110
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Il6
interleukin 6
increases expression multiple interactions
ISO EXP
carbendazim results in increased expression of IL6 mRNA; carbendazim results in increased expression of IL6 protein Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]
CTD
PMID:26071454 PMID:33965443
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Itga5
integrin subunit alpha 5
decreases expression
ISO
carbendazim results in decreased expression of ITGA5 mRNA
CTD
PMID:25530041
NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837
G
Itgb1
integrin subunit beta 1
decreases expression
ISO
carbendazim results in decreased expression of ITGB1 mRNA
CTD
PMID:25530041
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
G
Keap1
Kelch-like ECH-associated protein 1
multiple interactions increases expression
EXP
Chitosan inhibits the reaction [carbendazim results in increased expression of KEAP1 mRNA]
CTD
PMID:35705592
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
G
Lhb
luteinizing hormone subunit beta
decreases expression multiple interactions
EXP
carbendazim results in decreased expression of LHB protein Carnitine inhibits the reaction [carbendazim results in decreased expression of LHB protein]
CTD
PMID:33965443
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
G
Loxl1
lysyl oxidase-like 1
multiple interactions increases expression
EXP
2,5-hexanedione promotes the reaction [carbendazim results in increased expression of LOXL1 protein]; [carbendazim co-treated with 2,5-hexanedione] results in decreased expression of LOXL1 mRNA
CTD
PMID:22382377
NCBI chr 8:58,691,763...58,716,365
Ensembl chr 8:58,692,593...58,716,356
G
Lpl
lipoprotein lipase
decreases expression
ISO
carbendazim results in decreased expression of LPL protein
CTD
PMID:30496565
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
G
Macrod1
mono-ADP ribosylhydrolase 1
multiple interactions
EXP
[carbendazim co-treated with 2,5-hexanedione] results in decreased expression of MACROD1 mRNA
CTD
PMID:22382377
NCBI chr 1:204,246,238...204,387,027
Ensembl chr 1:204,246,166...204,389,716
G
Mapk1
mitogen activated protein kinase 1
affects localization
ISO
carbendazim affects the localization of MAPK1 protein modified form
CTD
PMID:37506866
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
G
Mapk3
mitogen activated protein kinase 3
affects localization
ISO
carbendazim affects the localization of MAPK3 protein modified form
CTD
PMID:37506866
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
G
Mapk8
mitogen-activated protein kinase 8
increases expression
EXP
carbendazim results in increased expression of MAPK8 mRNA
CTD
PMID:35513110
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
G
Mfap3l
microfibril associated protein 3 like
increases expression
EXP
carbendazim results in increased expression of MFAP3L mRNA
CTD
PMID:22952946
NCBI chr16:29,411,643...29,454,665
Ensembl chr16:29,415,849...29,430,863
G
Mir128-1
microRNA 128-1
increases expression
EXP
carbendazim results in increased expression of MIR128-1 mRNA
CTD
PMID:32418910
NCBI chr13:39,699,449...39,699,530
Ensembl chr13:39,699,449...39,699,530
G
Mir423
microRNA 423
increases expression
EXP
carbendazim results in increased expression of MIR423 mRNA
CTD
PMID:32418910
NCBI chr10:61,914,142...61,914,220
Ensembl chr10:61,914,133...61,914,226
G
Mmp2
matrix metallopeptidase 2
decreases expression
ISO
carbendazim results in decreased expression of MMP2 mRNA
CTD
PMID:25530041
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
G
Mmp9
matrix metallopeptidase 9
decreases expression
ISO
carbendazim results in decreased expression of MMP9 mRNA
CTD
PMID:25530041
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
G
Mpo
myeloperoxidase
multiple interactions increases activity
EXP
[Chlorpyrifos co-treated with carbendazim] results in increased activity of MPO protein carbendazim results in increased activity of MPO protein
CTD
PMID:27268782
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
G
Nfe2l2
NFE2 like bZIP transcription factor 2
increases expression multiple interactions decreases expression
ISO EXP
carbendazim results in increased expression of NFE2L2 protein Chitosan inhibits the reaction [carbendazim results in decreased expression of NFE2L2 mRNA]
CTD
PMID:30851412 PMID:35705592
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
G
Nos2
nitric oxide synthase 2
multiple interactions increases expression
EXP
Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Chitosan inhibits the reaction [carbendazim results in increased expression of NOS2 protein]
CTD
PMID:33965443 PMID:35705592
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
G
Nr1h4
nuclear receptor subfamily 1, group H, member 4
multiple interactions
ISO
carbendazim inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
CTD
PMID:25257666
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
G
Ocln
occludin
decreases expression multiple interactions
EXP
carbendazim results in decreased expression of OCLN protein Carnitine inhibits the reaction [carbendazim results in decreased expression of OCLN protein]
CTD
PMID:33965443
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
G
Pim1
Pim-1 proto-oncogene, serine/threonine kinase
increases expression
EXP
carbendazim results in increased expression of PIM1 mRNA
CTD
PMID:22952946
NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174
G
Plau
plasminogen activator, urokinase
decreases expression
ISO
carbendazim results in decreased expression of PLAU mRNA
CTD
PMID:25530041
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
G
Ptgds
prostaglandin D2 synthase
decreases expression
EXP
carbendazim results in decreased expression of PTGDS mRNA
CTD
PMID:22952946
NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833
G
Pttg1
PTTG1 regulator of sister chromatid separation, securin
increases expression
ISO
carbendazim results in increased expression of PTTG1 protein
CTD
PMID:37506866
NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
G
Rela
RELA proto-oncogene, NF-kB subunit
increases expression multiple interactions
EXP
carbendazim results in increased expression of RELA protein Carnitine inhibits the reaction [carbendazim results in increased expression of RELA protein]
CTD
PMID:33965443
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
G
Serpine2
serpin family E member 2
increases expression
ISO
carbendazim results in increased expression of SERPINE2 mRNA
CTD
PMID:25530041
NCBI chr 9:81,124,746...81,188,866
Ensembl chr 9:81,124,804...81,188,826
G
Shank3
SH3 and multiple ankyrin repeat domains 3
multiple interactions
EXP
[carbendazim co-treated with 2,5-hexanedione] affects the expression of SHANK3 mRNA
CTD
PMID:22382377
NCBI chr 7:120,568,707...120,630,796
Ensembl chr 7:120,570,402...120,630,374
G
Sil1
SIL1 nucleotide exchange factor
decreases expression
EXP
carbendazim results in decreased expression of SIL1 mRNA
CTD
PMID:22952946 PMID:27466211
NCBI chr18:26,872,423...27,104,365
Ensembl chr18:26,872,429...27,104,332
G
Sod3
superoxide dismutase 3
increases expression
EXP
carbendazim results in increased expression of SOD3 mRNA
CTD
PMID:27466211
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
G
Srebf1
sterol regulatory element binding transcription factor 1
increases expression
ISO
carbendazim results in increased expression of SREBF1 mRNA
CTD
PMID:26071454
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
G
Star
steroidogenic acute regulatory protein
decreases expression multiple interactions
EXP
carbendazim results in decreased expression of STAR mRNA; carbendazim results in decreased expression of STAR protein Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein]
CTD
PMID:33965443
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
G
Tbc1d5
TBC1 domain family, member 5
decreases expression
EXP
carbendazim results in decreased expression of TBC1D5 mRNA
CTD
PMID:27466211
NCBI chr 9:3,503,328...4,017,131
Ensembl chr 9:3,513,623...4,016,913
G
Timp1
TIMP metallopeptidase inhibitor 1
increases expression
ISO
carbendazim results in increased expression of TIMP1 mRNA
CTD
PMID:25530041
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
G
Timp2
TIMP metallopeptidase inhibitor 2
increases expression
ISO
carbendazim results in increased expression of TIMP2 mRNA
CTD
PMID:25530041
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
G
Tnf
tumor necrosis factor
multiple interactions increases expression
EXP
Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]
CTD
PMID:33965443 PMID:35437878 PMID:35513110
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Tnp1
transition protein 1
increases expression
EXP
carbendazim results in increased expression of TNP1 mRNA
CTD
PMID:28576679
NCBI chr 9:74,594,463...74,595,072
Ensembl chr 9:74,594,466...74,595,274
G
Tnp2
transition protein 2
increases expression
EXP
carbendazim results in increased expression of TNP2 mRNA
CTD
PMID:28576679
NCBI chr10:4,879,812...4,880,540
Ensembl chr10:4,879,812...4,880,538
G
Tp53
tumor protein p53
increases expression affects activity
EXP ISO
carbendazim results in increased expression of TP53 mRNA carbendazim affects the activity of TP53 protein
CTD
PMID:35435491 PMID:35513110
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Tshb
thyroid stimulating hormone subunit beta
increases expression
EXP
carbendazim results in increased expression of TSHB protein
CTD
PMID:33965443
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
G
Ahr
aryl hydrocarbon receptor
multiple interactions
ISO
diethofencarb binds to and results in increased activity of AHR protein
CTD
PMID:18835618
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
G
Acaca
acetyl-CoA carboxylase alpha
decreases expression
ISO
propamocarb results in decreased expression of ACACA mRNA
CTD
PMID:29137890
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
G
Ache
acetylcholinesterase
decreases expression
ISO
propamocarb results in decreased expression of ACHE protein
CTD
PMID:30251769
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
G
Acly
ATP citrate lyase
decreases expression
ISO
propamocarb results in decreased expression of ACLY mRNA
CTD
PMID:29137890
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
G
Acox1
acyl-CoA oxidase 1
decreases expression
ISO
propamocarb results in decreased expression of ACOX1 mRNA
CTD
PMID:29137890
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
G
Apoe
apolipoprotein E
multiple interactions
ISO
propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of CD36 protein]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of HMGCR mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of HMGCS1 mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of ICAM1 mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of ICAM1 protein]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IFNG mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IFNG protein]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IL10 mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IL1A mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IL1A protein]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IL1B mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IL1B protein]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IL6 mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of LDLR mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of SCARB1 mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TNF mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TNF protein]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of VCAM1 mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of VCAM1 protein]
CTD
PMID:34426332
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
G
Cd36
CD36 molecule
multiple interactions
ISO
propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of CD36 protein]
CTD
PMID:34426332
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
G
Cyp19a1
cytochrome P450, family 19, subfamily a, polypeptide 1
increases activity
ISO
propamocarb results in increased activity of CYP19A1 protein
CTD
PMID:11884232
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
G
Dgat2
diacylglycerol O-acyltransferase 2
decreases expression
ISO
propamocarb results in decreased expression of DGAT2 mRNA
CTD
PMID:29137890
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
G
Drd2
dopamine receptor D2
decreases expression
ISO
propamocarb results in decreased expression of DRD2 mRNA
CTD
PMID:30251769
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
G
Esr1
estrogen receptor 1
multiple interactions increases activity
ISO
[fludioxonil co-treated with N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide co-treated with propamocarb] results in increased activity of ESR1 protein propamocarb results in increased activity of ESR1 protein
CTD
PMID:26812056
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Esr2
estrogen receptor 2
multiple interactions increases activity
ISO
[fludioxonil co-treated with N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide co-treated with propamocarb] results in increased activity of ESR2 protein propamocarb results in increased activity of ESR2 protein
CTD
PMID:26812056
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
G
Fabp2
fatty acid binding protein 2
decreases expression
ISO
propamocarb results in decreased expression of FABP2 mRNA
CTD
PMID:29137890
NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089
G
Fasn
fatty acid synthase
decreases expression
ISO
propamocarb results in decreased expression of FASN mRNA
CTD
PMID:29137890
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
G
Ffar3
free fatty acid receptor 3
decreases expression
ISO
propamocarb results in decreased expression of FFAR3 mRNA
CTD
PMID:29137890
NCBI chr 1:86,105,388...86,106,728
Ensembl chr 1:86,104,920...86,106,849
G
Gk
glycerol kinase
decreases expression
ISO
propamocarb results in decreased expression of GK mRNA
CTD
PMID:29137890
NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631
G
Gpam
glycerol-3-phosphate acyltransferase, mitochondrial
decreases expression
ISO
propamocarb results in decreased expression of GPAM mRNA
CTD
PMID:29137890
NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639
G
Hmgcr
3-hydroxy-3-methylglutaryl-CoA reductase
increases expression multiple interactions
ISO
propamocarb results in increased expression of HMGCR mRNA propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of HMGCR mRNA]
CTD
PMID:34426332
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
G
Hmgcs1
3-hydroxy-3-methylglutaryl-CoA synthase 1
increases expression multiple interactions
ISO
propamocarb results in increased expression of HMGCS1 mRNA propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of HMGCS1 mRNA]; propamocarb promotes the reaction [Dietary Fats results in increased expression of HMGCS1 mRNA]
CTD
PMID:34426332
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
G
Icam1
intercellular adhesion molecule 1
multiple interactions increases expression
ISO
propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of ICAM1 mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of ICAM1 protein]; propamocarb promotes the reaction [Dietary Fats results in increased expression of ICAM1 mRNA] propamocarb results in increased expression of ICAM1 mRNA
CTD
PMID:34426332
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
G
Ifng
interferon gamma
increases expression multiple interactions
ISO
propamocarb results in increased expression of IFNG protein propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IFNG mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IFNG protein]
CTD
PMID:34426332
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
G
Il10
interleukin 10
multiple interactions
ISO
propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IL10 mRNA]
CTD
PMID:34426332
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
G
Il1a
interleukin 1 alpha
multiple interactions
ISO
propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IL1A mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IL1A protein]
CTD
PMID:34426332
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
G
Il1b
interleukin 1 beta
increases expression multiple interactions
ISO
propamocarb results in increased expression of IL1B protein propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IL1B mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IL1B protein]; propamocarb promotes the reaction [Dietary Fats results in increased expression of IL1B mRNA]; propamocarb promotes the reaction [Dietary Fats results in increased expression of IL1B protein]
CTD
PMID:34426332
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Il6
interleukin 6
increases expression multiple interactions
ISO
propamocarb results in increased expression of IL6 mRNA; propamocarb results in increased expression of IL6 protein propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of IL6 mRNA]; propamocarb promotes the reaction [Dietary Fats results in increased expression of IL6 protein]
CTD
PMID:34426332
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Ldlr
low density lipoprotein receptor
multiple interactions
ISO
propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of LDLR mRNA]
CTD
PMID:34426332
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
G
Lpl
lipoprotein lipase
increases expression
ISO
propamocarb results in increased expression of LPL mRNA
CTD
PMID:29137890
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
G
Mlxipl
MLX interacting protein-like
decreases expression
ISO
propamocarb results in decreased expression of MLXIPL mRNA
CTD
PMID:29137890
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
G
Pklr
pyruvate kinase L/R
decreases expression
ISO
propamocarb results in decreased expression of PKLR mRNA
CTD
PMID:29137890
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
G
Pparg
peroxisome proliferator-activated receptor gamma
decreases expression
ISO
propamocarb results in decreased expression of PPARG mRNA
CTD
PMID:29137890
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
G
Scarb1
scavenger receptor class B, member 1
multiple interactions increases expression
ISO
propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of SCARB1 mRNA]; propamocarb promotes the reaction [Dietary Fats results in increased expression of SCARB1 mRNA] propamocarb results in increased expression of SCARB1 mRNA
CTD
PMID:34426332
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
G
Scd
stearoyl-CoA desaturase
decreases expression
ISO
propamocarb results in decreased expression of SCD1 mRNA
CTD
PMID:29137890
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
G
Slc27a2
solute carrier family 27 member 2
decreases expression
ISO
propamocarb results in decreased expression of SLC27A2 mRNA
CTD
PMID:29137890
NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208
G
Srebf1
sterol regulatory element binding transcription factor 1
decreases expression
ISO
propamocarb results in decreased expression of SREBF1 mRNA
CTD
PMID:29137890
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
G
Tnf
tumor necrosis factor
increases expression multiple interactions
ISO
propamocarb results in increased expression of TNF mRNA; propamocarb results in increased expression of TNF protein [Dietary Fats co-treated with propamocarb] results in increased expression of TNF protein; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TNF mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TNF protein]; propamocarb promotes the reaction [Dietary Fats results in increased expression of TNF mRNA]
CTD
PMID:34426332
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Tph2
tryptophan hydroxylase 2
decreases expression
ISO
propamocarb results in decreased expression of TPH2 mRNA
CTD
PMID:30251769
NCBI chr 7:50,685,694...50,789,424
Ensembl chr 7:50,685,694...50,789,424
G
Vcam1
vascular cell adhesion molecule 1
increases expression multiple interactions
ISO
propamocarb results in increased expression of VCAM1 mRNA propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of VCAM1 mRNA]; propamocarb affects the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of VCAM1 protein]; propamocarb promotes the reaction [Dietary Fats results in increased expression of VCAM1 mRNA]
CTD
PMID:34426332
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
G
Abcc2
ATP binding cassette subfamily C member 2
multiple interactions
ISO
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of ABCC2 mRNA
CTD
PMID:32745781
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
G
Abcc3
ATP binding cassette subfamily C member 3
multiple interactions
ISO
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of ABCC3 mRNA
CTD
PMID:32745781
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
G
Acox1
acyl-CoA oxidase 1
multiple interactions
ISO
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of ACOX1 mRNA
CTD
PMID:32736067
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
G
Alb
albumin
affects binding
ISO
Thiophanate binds to ALB protein
CTD
PMID:19121585
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
G
Cd36
CD36 molecule
multiple interactions
ISO
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CD36 mRNA
CTD
PMID:32736067
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
G
Cpt1a
carnitine palmitoyltransferase 1A
multiple interactions
ISO
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CPT1A mRNA
CTD
PMID:32736067
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
G
Cyp1a1
cytochrome P450, family 1, subfamily a, polypeptide 1
increases expression
EXP
Thiophanate results in increased expression of CYP1A1 protein
CTD
PMID:10096430
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
G
Cyp1a2
cytochrome P450, family 1, subfamily a, polypeptide 2
increases expression
EXP
Thiophanate results in increased expression of CYP1A2 protein
CTD
PMID:10096430
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
G
Cyp2b1
cytochrome P450, family 2, subfamily b, polypeptide 1
affects expression
EXP
Thiophanate affects the expression of CYP2B1 protein
CTD
PMID:10096430
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
G
Cyp2b3
cytochrome P450, family 2, subfamily b, polypeptide 3
multiple interactions
ISO
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2B10 mRNA; [Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2B10 mRNA
CTD
PMID:32736067 PMID:32745781
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
G
Cyp2c24
cytochrome P450, family 2, subfamily c, polypeptide 24
multiple interactions
ISO
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2C55 mRNA
CTD
PMID:32736067
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
G
Cyp2c6
cytochrome P450, family 2, subfamily C, polypeptide 6
multiple interactions
ISO
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2C29 mRNA
CTD
PMID:32745781
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
G
Cyp2e1
cytochrome P450, family 2, subfamily e, polypeptide 1
increases expression
EXP
Thiophanate results in increased expression of CYP2E1 protein
CTD
PMID:10096430
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
G
Dio1
iodothyronine deiodinase 1
multiple interactions
ISO
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of DIO1 mRNA
CTD
PMID:32745781
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
G
Eci1
enoyl-CoA delta isomerase 1
multiple interactions
ISO
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of ECI1 mRNA
CTD
PMID:32736067
NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
G
Gfap
glial fibrillary acidic protein
multiple interactions
ISO
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of GFAP protein
CTD
PMID:32736067
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
G
Hmgcs2
3-hydroxy-3-methylglutaryl-CoA synthase 2
multiple interactions
ISO
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of HMGCS2 mRNA
CTD
PMID:32745781
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
G
Ins1
insulin 1
multiple interactions
ISO
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of INS1 protein
CTD
PMID:32745781
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
G
Nr1i3
nuclear receptor subfamily 1, group I, member 3
multiple interactions
ISO
NR1I3 protein affects the susceptibility to [2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with Thiophanate co-treated with thiacloprid co-treated with Ziram]
CTD
PMID:29950287
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
G
Pdgfrb
platelet derived growth factor receptor beta
multiple interactions
ISO
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of PDGFRB protein
CTD
PMID:32736067
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
G
Ptgs2
prostaglandin-endoperoxide synthase 2
affects expression
EXP
Thiophanate affects the expression of PTGS2
CTD
PMID:28364781
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
G
Serpine1
serpin family E member 1
multiple interactions
ISO
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SERPINE1 mRNA
CTD
PMID:32745781
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
G
Slc16a2
solute carrier family 16 member 2
multiple interactions
ISO
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SLC16A2 mRNA
CTD
PMID:32745781
NCBI chr X:68,725,365...68,848,572
Ensembl chr X:68,723,261...68,848,771
G
Sult1b1
sulfotransferase family 1B member 1
multiple interactions
ISO
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SULT1B1 mRNA
CTD
PMID:32745781
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
G
Thrsp
thyroid hormone responsive
multiple interactions
ISO
[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of THRSP mRNA; [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in decreased expression of THRSP mRNA; Dietary Fats inhibits the reaction [[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of THRSP mRNA]
CTD
PMID:32745781
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all